ZS17 activates the ROS-JNK-p53 pathway, inhibits mitochondrial oxidative phosphorylation, induces apoptosis, and may further lead to mitochondrial dysfunction in tumour cells by inhibiting ATP production by HCC cells. This evidence concerns the gene TP53 and hepatocellular carcinoma.